Nicas ( Non Invasive Cardiac System )

NICaS (Non-Invasive Cardiac System) is a cutting-edge hemodynamic monitoring device developed by NI Medical (Israel), designed to bring precision cardiovascular diagnostics into everyday clinical practice — without the complexity, cost, or risk of invasive procedures.

Using Regional Whole-Body Impedance Cardiography, NICaS requires only two sensors placed on the wrist and contralateral ankle. In just 4–6 minutes, it delivers a comprehensive hemodynamic profile that would otherwise require multiple tests or invasive catheterization. The device is fully operator-independent, self-verifying before each use, and requires no mechanical calibration — making it accessible across a wide range of clinical settings.

What it measures goes far beyond a standard ECG or blood pressure cuff: cardiac output, stroke volume, cardiac index, total peripheral resistance, cardiac power index, LV function (via the Granov-Goor Index), total body water, respiration rate, and more — all from a single, non-invasive test.

Its most transformative application is in hypertension management. NICaS classifies patients into three distinct hemodynamic phenotypes — vasoconstriction, hyperdynamic, and mixed — enabling physicians to match the right drug class to the right patient from the outset. This approach drove a 92% blood pressure control rate in the PriMED cohort (vs. the US average of 44%), as demonstrated in a landmark real-world study of 14,698 patients over 10 years, presented at ESC Congress 2023 in Amsterdam and ESC 2024 in London.

Beyond hypertension, NICaS is clinically validated in heart failure (90% reduction in readmissions), dialysis (dry weight optimization, prevention of intradialytic hypotension), preeclampsia, ICU/ICCU monitoring, COVID-19, CRT optimization, and pharmaceutical clinical trials.

NICaS holds regulatory approvals in the USA (FDA 510(k)), Europe (CE Mark), Japan (PMDA), Canada, China (CFDA), Australia (TGA), Singapore, and Thailand, and is billed under CPT Code 93701. Trusted institutions including Mayo Clinic, Imperial College London, Duke University, and Singapore General Hospital have adopted it in research and clinical care.

In short, NICaS transforms cardiovascular diagnostics from a specialized, resource-intensive process into a fast, accurate, and universally deployable clinical tool — putting the right hemodynamic data in the hands of clinicians at the point of care.